GlobeNewswire Inc | Nov 11, 2021 04:05PM EST

November 11, 2021

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate virtually at the 2021 Jefferies London Healthcare Conference.

2021 Jefferies London Healthcare ConferenceFormat: Virtual presentation and investor 1x1 meetingsThe presentation will be available on-demand starting Thursday, November 18, 2021, at 8:00am GMT / 3:00am ET through Friday, November 19, 2021, at 5:00pm GMT / 12:00pm ET.

Please find a link to the presentation here.

A webcast can also be accessed under Events & Presentations in the Investors section of the Companys website, www.foghorntx.com

About Foghorn Therapeutics

FoghornTherapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Controlplatform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavali, Foghorn Therapeutics Inc.fcavalie@foghorntx.com

Gregory Kelley, Ogilvygregory.kelley@ogilvy.com

Investor Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.bstrain@foghorntx.com

Hans Vitzthum, LifeSci Advisors617-430-7578hans@lifesciadvisors.com